LOMUSTINE , Odomzo 200 mg hard capsules, VINCRISTINE, CISPLATIN clinical trials

EORTC 1634-BTG (NOA-23): Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)

This study looks at a new way to treat médulloblastoma, a type of brain cancer, in adults. It compares a personalised treatment to the standard one, aiming to find better ways to help patients live longer and improve their quality of life.